788 related articles for article (PubMed ID: 26386686)
41. Ulcerative colitis: prevention of relapse.
Naganuma M; Sakuraba A; Hibi T
Expert Rev Gastroenterol Hepatol; 2013 May; 7(4):341-51. PubMed ID: 23639092
[TBL] [Abstract][Full Text] [Related]
42. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
43. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis.
Jackson B; De Cruz P
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1079-1100. PubMed ID: 30284911
[TBL] [Abstract][Full Text] [Related]
44. Maneuvering Clinical Pathways for Ulcerative Colitis.
Johnson CM; Linzay CD; Dassopoulos T
Curr Gastroenterol Rep; 2019 Sep; 21(10):52. PubMed ID: 31486929
[TBL] [Abstract][Full Text] [Related]
45. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
[TBL] [Abstract][Full Text] [Related]
46. Recent trends and future directions for the medical treatment of ulcerative colitis.
Naganuma M; Mizuno S; Nanki K; Sugimoto S; Kanai T
Clin J Gastroenterol; 2016 Dec; 9(6):329-336. PubMed ID: 27699641
[TBL] [Abstract][Full Text] [Related]
47. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence.
Bezzio C; Festa S; Saibeni S; Papi C
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):339-347. PubMed ID: 28165825
[TBL] [Abstract][Full Text] [Related]
48. Novel oral-targeted therapies for mucosal healing in ulcerative colitis.
Antonelli E; Villanacci V; Bassotti G
World J Gastroenterol; 2018 Dec; 24(47):5322-5330. PubMed ID: 30598577
[TBL] [Abstract][Full Text] [Related]
49. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
50. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
[TBL] [Abstract][Full Text] [Related]
51. Nursing management of patients with severe ulcerative colitis.
Sephton M
Nurs Stand; 2009 Dec 16-2010 Jan 5; 24(15-17):48-57; quiz 58, 60. PubMed ID: 20162907
[TBL] [Abstract][Full Text] [Related]
52. Ulcerative colitis-associated colorectal cancer.
Yashiro M
World J Gastroenterol; 2014 Nov; 20(44):16389-97. PubMed ID: 25469007
[TBL] [Abstract][Full Text] [Related]
53. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
[TBL] [Abstract][Full Text] [Related]
54. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
55. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2.
Tanida S; Mizoshita T; Ozeki K; Katano T; Kataoka H; Kamiya T; Joh T
World J Gastroenterol; 2015 Aug; 21(29):8776-86. PubMed ID: 26269667
[TBL] [Abstract][Full Text] [Related]
56. Update on idiopathic colitides.
Strobel S; Abreu MT
Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
[TBL] [Abstract][Full Text] [Related]
57. [Second Korean Guideline for the Management of Ulcerative Colitis].
Choi CH; Moon W; Kim YS; Kim ES; Lee BI; Jung Y; Yoon YS; Lee H; Park DI; Han DS;
Korean J Gastroenterol; 2017 Jan; 69(1):1-28. PubMed ID: 28135789
[TBL] [Abstract][Full Text] [Related]
58. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
[TBL] [Abstract][Full Text] [Related]
59. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Conrad MA; Kelsen JR
Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
[TBL] [Abstract][Full Text] [Related]
60. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
